How two professors imagine a better world for stakeholders in the medical industry.
Blog
-
September 17, 2018Read more »
-
September 17, 2018Read more »
"These results offer a leap in understanding about this disease that provides a genetically based framework for designing clinical trials to develop more effective treatments of MPAL,"

-
September 17, 2018Read more »
"In short, it will help produce drugs where we can be far more confident about where modifications are being made, so that side effects can be minimized in the future"

-
August 31, 2018Read more »
Researchers report a successful classification of triple breast cancer patients, which for the first time, would allow doctors to discern between those who can be cured and those who might suffer a relapse.

-
Read more »
According to study investigators, about a third of patients could benefit from this therapy that may offer remissions, relieve symptoms and save lives. -
Read more »
"This is a great avenue of exploration, particularly for the 30 percent of children who struggle or don't make it with standard therapy."

-
August 30, 2018Read more »
These findings increase our understanding of how the brain is affected by Parkinson's disease...

-
Read more »
"These findings provide a glimmer of hope for people with a form of multiple sclerosis that causes long-term disability but does not have many treatment options,"

-
August 29, 2018Read more »
"By laying the groundwork for more rational design and deeper understanding of focused-ultrasound-based treatment, our work could help improve treatment of any brain tumor -- primary or metastatic -- and could also revolutionize approaches to immunotherapy of tumors by improving localized delivery of tumor-killing immune cells."

-
Read more »
"These findings of incredible mental flourishing even in the context of cancer is a wonderful testament to the resiliency of patients and an encouraging message for patients, their families and their health care providers" stated Fuller-Thomson.

-
August 27, 2018Read more »
"The best part is that our combined drug candidate was so much more effective than one of the most powerful cancer drugs on the market," said Jonathan Sessler

-
August 27, 2018Read more »
"We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice's leukemia signs disappeared overnight," said Professor Ben-Neriah.

-
August 24, 2018Read more »
"Our findings could provide an opportunity to improve future engineering of CAR T cells against tumors...."

-
August 23, 2018Read more »
"We believe we've found an approach that is most relevant to humans, in that our models of gene dysfunction mimic the etiology of Parkinson's disease rather than its pathology....

-
August 23, 2018Read more »
This opens up new treatment strategies for diseases that involve impairment of the body's ability to break down...

-
August 23, 2018Read more »
The breakthrough provides a better understanding of the individualized nature of the disease says the research team.

-
August 07, 2018Read more »
Lower prices negotiated and provided as part of our ongoing mission to make medicines more accessible.
-
August 02, 2018Read more »
2018 has been a good year for new cancer treatments says the U.S. AACR.
-
August 02, 2018Read more »
Kisqali is now the only CDK4/6 inhibitor for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US. -
Read more »
The approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome.

-
Read more »
The new preventive medicine for migraine Aimovig (erenumab) has been approved by the EMA. Read more...
-
July 24, 2018Read more »
7 need-to-knows about migraine as well as some updates on the latest treatment developments

-
July 20, 2018
-
July 20, 2018
-
Read more »
The dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. -
Read more »
It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments. -
Read more »
Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients. -
July 04, 2018Read more »
The latest approval renders the previous 'temporary approval' a full approval, without further results needed. -
July 04, 2018Read more »
The 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%. -
July 04, 2018Read more »
The FDA has approved a wearable device to treat withdrawal symptoms such as agitation, anxiety, depression, and opiate cravings.
Experts in novel medicines